65 unknown, 16 completed, 4 not yet recruiting, 2 recruiting. 67 Phase 2, 11 Phase 3, 7 Phase 4, 5 Phase 1, 2 Not applicable.
Follow endostar protein: new trials by email Literature Review of endostar protein trials Research Report on endostar protein
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC Stereotactic Radiation Therapy, Envafolimab, Endostar - Non Small Cell Lung Cancer, Lung Neoplasms | Phase 2 | Not yet recruiting | The First People's Hospital of Lianyungang | 61 | 2026-10-01 | 2026-09-14 |
| Early Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases Recombinant Human Endostatin (Endostar) - Lung Cancer (Non-Small Cell), Radiation | Phase 2 | Not yet recruiting | Jiangmen Central Hospital | 49 | 2026-09-01 | 2026-10-01 |
| Platinum-Free Regimen in Nasopharyngeal Carcinoma Endostar (recombinant human endostatin injection) - Nasopharyngeal Cancinoma (NPC) | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 145 | 2026-09-01 | 2026-08-31 |
| Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial Toripalimab combined with Endostar - Melanoma of Skin, Acral Melanoma | Phase 2 | Recruiting | Fudan University | 58 | 2025-01-01 | 2025-05-11 |
| Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) - Osteosarcoma, Bone Cancer | Phase 1 / Phase 2 | Completed | Shanghai 6th People's Hospital | 10 | 2024-12-03 | 2025-12-29 |
| Local Injection and Systemic Therapy in the Treatment of NSCLC. Envafolimab, Recombinant human endostatin, recombinant human adenovirus type 5 - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Henan Cancer Hospital | 84 | 2024-10-08 | 2024-10-01 |
| Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy, surgery, Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar) - Unresectable Non-small Cell Lung Cancer | Phase 2 | Recruiting | Hua Zhang | 36 | 2024-08-27 | 2025-07-15 |
| Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors Envafolimab Injection, Endostar - Gastrointestinal Neoplasms | Phase 2 | Unknown | Nanjing First Hospital, Nanjing Medical University | 16 | 2024-02-21 | 2024-03-08 |
| Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma Endostar and Envafolimab - Nasopharyngeal Carcinoma | Phase 2 | Active not recruiting | Zhejiang Cancer Hospital | 40 | 2023-10-24 | 2026-10-06 |
| A Study of Endostar Combined With Chemotherapy and Immunotherapy in Lung Squamous Cell Carcinom To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV). - Lung Squamous Cell Carcinoma | Phase 4 | Unknown | Xuzhou Medical University | 30 | 2023-06-01 | 2023-03-24 |
| Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer cis-platinum, radiation, Envafolimab Injection - Cervical Cancer | Unknown | Peking University Third Hospital | 30 | 2023-05-16 | 2023-05-30 | |
| Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer Envafolimab plus Endostar and S-1, Envafolimab plus Endostar, Envafolimab plus S-1 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | Anhui Chest Hospital | 45 | 2022-09-18 | 2022-09-07 |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Envafolimab, Endostar, Nab paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2022-04-01 | 2022-03-28 |
| Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC Envafolimab, Endostar - Lung Neoplasms | Phase 2 | Unknown | The First People's Hospital of Lianyungang | 40 | 2022-03-01 | 2023-06-22 |
| PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy Endostar, use the vein pump to pump drugs, combination therapy - Advanced or Metastatic NSCLC | Phase 1 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 24 | 2021-07-30 | 2021-06-30 |
| Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Endostar - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Jiangxi Provincial Cancer Hospital | 30 | 2021-07-28 | 2022-01-04 |
| First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial Recombinant human endostatin (Endostar) - Non-Small-Cell Lung Cancer | Phase 2 | Unknown | Qianfoshan Hospital | 100 | 2021-02-01 | 2022-10-12 |
| Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC Recombinant human endostatin (Endostar), Thoracic irradiation of 50 Gy with 3DCRT or IMRT - Lung Cancer | Phase 4 | Unknown | Shanghai Chest Hospital | 97 | 2020-12-01 | 2020-11-03 |
| Endostar Combined With AI Regimen Compared With AI in Adjuvant Treatment Endostar (recombinant human endostatin injection), Chemotherapy AI - Other Disorders of Soft Tissues | Phase 2 | Unknown | Yong Chen | 210 | 2020-09-01 | 2021-01-07 |
| Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma Toripalimab, chemotherapy in combination with Endostar - Mucosal Melanoma | Phase 2 | Unknown | Fudan University | 31 | 2020-06-20 | 2020-07-15 |
Showing 20 of 89. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (22) · Lung Neoplasms (8) · Nasopharyngeal Carcinoma (8) · Colorectal Neoplasms (4) · Breast Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Melanoma (3) · Uterine Cervical Neoplasms (3) · Esophageal Neoplasms (2) · Lymphoma, T-Cell (2) · Lymphoma, T-Cell, Peripheral (2) · Nasopharyngeal Neoplasms (2) · Osteosarcoma (2) · Sarcoma (2) · Adenocarcinoma of Lung (1)
Fudan University (8) · Zhejiang Cancer Hospital (7) · Jiangsu Simcere Pharmaceutical Co., Ltd. (6) · Simcere Pharmaceutical Co., Ltd (4) · First Affiliated Hospital of Guangxi Medical University (3) · Nanjing NingQi Medicine Science and Technology Co., Ltd. (3) · Peking University Third Hospital (3) · Tianjin Medical University Cancer Institute and Hospital (3) · Peking University Cancer Hospital & Institute (2) · Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd (2) · Shanghai Jiao Tong University School of Medicine (2) · Sun Yat-sen University (2) · The First People's Hospital of Lianyungang (2) · Xinqiao Hospital of Chongqing (2) · Zhejiang University (2)
China (78)
Xiaodong Jiang, MD (2) · Bin Li (1) · Changgui Wu, MD, PHD (1) · Chunmeng Wang, Dr. (1) · Daiyuan Ma, M.D (1) · Degan Lu, professor (1) · Dong Wang, PH.D (1) · Fei Han, M.D., Ph.D. (1) · Feng Shen, M.D. (1) · Gu Yanhong, PI (1) · Guo Jun, PI (1) · Guoliang Jiang, MD (1) · Hanmei Lou, PHD (1) · Hong-Tao Li, Dr. (1)
PMID 10640954, PMID 11212235, PMID 15172975, PMID 15746043, PMID 15752890, PMID 15920746, PMID 16012180, PMID 16139912, PMID 16807466, PMID 19564532, PMID 19692680, PMID 21108883, PMID 22099051, PMID 22209574, PMID 22496834, PMID 22537906, PMID 22562140, PMID 23670576, PMID 25198661, PMID 25244494, PMID 25497558, PMID 26434908, PMID 27067521, PMID 27566586, PMID 30773184, PMID 35380726, PMID 38700579, PMID 41014160, PMID 41049580